查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600679

隱球菌病市場：依治療方法、通路分類 - 全球預測 2025-2030

Cryptococcosis Market by Treatment (Amphotericin B, Fluconazole, Flucytosine), Distribution Channel (Hospital Pharmacies, Mail Order Pharmacies, Retail Pharmacies & Drug Stores) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年隱球菌病市場價值為59.1億美元，預計到2024年將達到63.5億美元，複合年成長率為7.64%，預計到2030年將達到99億美元。

隱球菌病是嚴重的真菌感染疾病，主要影響免疫力的人群，特別是愛滋病毒/愛滋病患者，並在全世界構成重大健康挑戰。免疫力缺乏低下個體數量的增加和對真菌感染疾病認知的提高強調需要有效的隱球菌病診斷和治療解決方案。治療應用整體醫療保健產業，重點在於診斷工具、抗真菌藥物和免疫療法。最終用途集中在醫院、專科診所和研究機構，其中準確的診斷和有效的治療至關重要。市場成長受到診斷測試技術進步、醫療保健支出增加以及新型療法的出現等因素的顯著影響。潛在的商機在於擴大快速、準確診斷的範圍，並提高抗真菌藥物的有效性，以惠及發展中地區服務不足的人。鼓勵公司投資行動診所並與當地醫療保健提供者夥伴關係，以覆蓋更多人並改善就診機會。然而，挑戰依然存在，例如資源匱乏環境下的意識低、治療成本高、抗藥性菌株的出現。新藥認證的監管障礙也可能阻礙市場成長。在更有效的疫苗研究和對抗抗藥性菌株的生物技術進步方面，創新機會比比皆是。探索基因組技術以更好地了解病原體抗藥性機制並提供個人化治療具有巨大潛力。最終，市場動態呈現出一個充滿活力的格局，在全球衛生優先事項的更廣泛背景下提供了巨大的成長機會。透過利用策略夥伴關係關係、專注於永續和創新的醫療保健解決方案以及解決經濟和監管障礙，公司可以響應並利用隱球菌病市場不斷變化的需求，並最終為改善公共衛生和擴大市場做出貢獻。

主要市場統計
基準年[2023] 59.1億美元
預測年份 [2024] 63.5億美元
預測年份 [2030] 99億美元
複合年成長率（%） 7.64%

市場動態：揭示快速發展的隱球菌病市場的關鍵市場洞察

供需的動態交互作用正在改變隱球菌病市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 感染疾病和致命性真菌疾病的盛行率增加
    • 對愛滋病毒/愛滋病相關隱球菌病的深入了解
    • 學名藥的供應量增加
  • 市場限制因素
    • 患者對治療的臨床認知有限
    • 由於感染隱球菌病的患者死亡率增加，檢測和診斷範圍縮小
  • 市場機會
    • 開發隱球菌腦膜炎有效治療方法的政府優惠計劃
    • 增加隱球菌病的藥物開發和臨床試驗生態系統開發
  • 市場挑戰
    • 與使用隱球菌病藥物相關的副作用
    • 製藥公司無法滿足需求且藥物開發專案資金不足

波特的五力：駕馭隱球菌病市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解隱球菌病市場的外部影響

外部宏觀環境因素在塑造隱球菌病市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解隱球菌病市場的競爭狀況

對隱球菌病市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣腳本 Coccosis 市場供應商的績效評估

FPNV定位矩陣是評估隱球菌市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病和致命真菌病的盛行率增加
      • 關於愛滋病毒/愛滋病相關隱球菌病的新發現
      • 提高學名藥的供應
    • 抑制因素
      • 患者臨床治療意識的局限性
      • 由於感染患者死亡率增加，檢測和診斷範圍縮小
    • 機會
      • 政府首選計劃開發隱球菌腦膜炎的有效治療方法
      • 隱球菌病藥物開發的增加和臨床試驗生態系統的演變
    • 任務
      • 與使用隱球菌病藥物相關的副作用
      • 由於製藥公司無法滿足需求，藥物開發計畫資金不足
  • 市場區隔分析
    • 治療：Amphotericin B主要用於治療嚴重的隱球菌病病例。
    • 分銷管道：零售藥局是輕鬆快速取得隱球菌病藥物的好選擇。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章 隱球菌病市場（依治療）

  • 兩性黴素B
  • Fluconazole
  • Flucytosine

第7章 隱球菌病市場：按分銷管道

  • 醫院藥房
  • 通訊藥房
  • 零售藥局/藥局

第8章美洲隱球菌病市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區隱球菌病市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲的隱球菌病市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Astellas來製藥完成對 Propeller Therapeutics 的收購
    • 諾華透過收購 DTx Pharma 加強神經科學產品線和 xRNA 平台能力
    • 葛蘭素史克同意收購後期生物製藥公司 BELLUS Health

公司名單

  • Bausch Health Companies Inc.
  • Astellas Pharma Inc.
  • Citron Pharma
  • Novartis AG
  • Glenmark Pharmaceuticals Limited
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Sigmapharm Laboratories, LLC
  • Skyepharma Production SAS
  • Pfizer Inc.
  • Sumitomo Pharma Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • NuCare Pharmaceuticals, Inc.
  • Lunan Pharmaceutical Group
  • BM Pharmaceuticals
  • Merck & Co., Inc.
  • Matinas Biopharma Holdings, Inc.
  • Gilead Sciences, Inc.
  • Sanofi SA
  • Jolly Limited
  • Abbott Laboratories
  • GlaxoSmithKline PLC
Product Code: MRR-4348D129F9A0

The Cryptococcosis Market was valued at USD 5.91 billion in 2023, expected to reach USD 6.35 billion in 2024, and is projected to grow at a CAGR of 7.64%, to USD 9.90 billion by 2030.

Cryptococcosis, a serious fungal infection primarily affecting individuals with compromised immune systems, particularly those with HIV/AIDS, poses critical health challenges worldwide. The growing prevalence of immunocompromised individuals and increased awareness about fungal infections underscore the market necessity for effective diagnostic and therapeutic solutions against cryptococcosis. Applications span the healthcare industry, focusing on diagnostic tools, antifungal drugs, and immunotherapy treatments. End-use extends primarily to hospitals, specialty clinics, and research institutions where accurate diagnosis and efficient treatment are imperative. Market growth is significantly influenced by factors like technological advancements in diagnostic testing, increasing healthcare expenditure, and the rise of novel therapeutics. Potential opportunities lie in expanding access to rapid and accurate diagnostic methods and enhancing antifungal drug efficacy to reach underserved populations in developing regions. One recommendation is for companies to invest in mobile health clinics and partnerships with local healthcare providers to improve reach and accessibility. However, challenges persist, including limited awareness in low-resource settings, the high cost of treatment, and the development of drug-resistant strains. The regulatory hurdles in new drug approvals can also impede market growth. Innovation opportunities abound in research for more effective vaccines and biotechnological advancements to counteract resistant strains. There is substantial potential in exploring genomic technologies to understand the pathogen's resistance mechanisms better and tailoring individualized therapy. Ultimately, the cryptococcosis market presents a dynamic landscape with significant opportunities for growth, vested in the broader context of global health priorities. By leveraging strategic partnerships, focusing on sustainable and innovative healthcare solutions, and addressing economic and regulatory barriers, businesses can navigate and capitalize on the evolving demands of the cryptococcosis market, ultimately contributing to public health improvements and market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 5.91 billion
Estimated Year [2024] USD 6.35 billion
Forecast Year [2030] USD 9.90 billion
CAGR (%) 7.64%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cryptococcosis Market

The Cryptococcosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing Prevalence of Infectious Diseases and Fatal Fungal Disease
    • Rising Insights into HIV/AIDS-Associated Cryptococcosis
    • Increasing Availability of Generic and Over-the-Counter Medicine
  • Market Restraints
    • Limited Clinical Awareness in Patients Regarding Treatments
    • Reduced Scope of Testing and Diagnostics due to Increased Mortality Among Cryptococcosis Infected Patients
  • Market Opportunities
    • Favorable Government Programs for the Development of Effective Therapeutics for Cryptococcal Meningitis Disease
    • Increasing Drug Development and Evolving Clinical Trial Ecosystem for Cryptococcosis
  • Market Challenges
    • Side Effects Associated with The Usage of Cryptococcosis Drugs
    • Pharmaceutical Companies Failing to Address The Need and Poorly Funded Drug Development Programs

Porter's Five Forces: A Strategic Tool for Navigating the Cryptococcosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cryptococcosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cryptococcosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cryptococcosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cryptococcosis Market

A detailed market share analysis in the Cryptococcosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cryptococcosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cryptococcosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cryptococcosis Market, highlighting leading vendors and their innovative profiles. These include Bausch Health Companies Inc., Astellas Pharma Inc., Citron Pharma, Novartis AG, Glenmark Pharmaceuticals Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Bayer AG, Sigmapharm Laboratories, LLC, Skyepharma Production SAS, Pfizer Inc., Sumitomo Pharma Co., Ltd., Johnson & Johnson Services, Inc., NuCare Pharmaceuticals, Inc., Lunan Pharmaceutical Group, B.M. Pharmaceuticals, Merck & Co., Inc., Matinas Biopharma Holdings, Inc., Gilead Sciences, Inc., Sanofi S.A., Jolly Limited, Abbott Laboratories, and GlaxoSmithKline PLC.

Market Segmentation & Coverage

This research report categorizes the Cryptococcosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Amphotericin B, Fluconazole, and Flucytosine.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Mail Order Pharmacies, and Retail Pharmacies & Drug Stores.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Prevalence of Infectious Diseases and Fatal Fungal Disease
      • 5.1.1.2. Rising Insights into HIV/AIDS-Associated Cryptococcosis
      • 5.1.1.3. Increasing Availability of Generic and Over-the-Counter Medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Limited Clinical Awareness in Patients Regarding Treatments
      • 5.1.2.2. Reduced Scope of Testing and Diagnostics due to Increased Mortality Among Cryptococcosis Infected Patients
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable Government Programs for the Development of Effective Therapeutics for Cryptococcal Meningitis Disease
      • 5.1.3.2. Increasing Drug Development and Evolving Clinical Trial Ecosystem for Cryptococcosis
    • 5.1.4. Challenges
      • 5.1.4.1. Side Effects Associated with The Usage of Cryptococcosis Drugs
      • 5.1.4.2. Pharmaceutical Companies Failing to Address The Need and Poorly Funded Drug Development Programs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Amphotericin B primarily and significantly used to treat the vital cases of cryptococcosis
    • 5.2.2. Distribution Channel: Retail pharmacies are good option for easy and quick availability of cryptococcosis medications
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Cryptococcosis Market, by Treatment

  • 6.1. Introduction
  • 6.2. Amphotericin B
  • 6.3. Fluconazole
  • 6.4. Flucytosine

7. Cryptococcosis Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Mail Order Pharmacies
  • 7.4. Retail Pharmacies & Drug Stores

8. Americas Cryptococcosis Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cryptococcosis Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cryptococcosis Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Astellas Completes Acquisition of Propella Therapeutics
    • 11.3.2. Novartis Builds on Neuroscience Pipeline and xRNA Platform Capabilities with Acquisition of DTx Pharma
    • 11.3.3. GSK Reaches Agreement to Acquire Late-stage Biopharmaceutical Company BELLUS Health

Companies Mentioned

  • 1. Bausch Health Companies Inc.
  • 2. Astellas Pharma Inc.
  • 3. Citron Pharma
  • 4. Novartis AG
  • 5. Glenmark Pharmaceuticals Limited
  • 6. Viatris Inc.
  • 7. Teva Pharmaceutical Industries Ltd.
  • 8. Bristol-Myers Squibb Company
  • 9. Eisai Co., Ltd.
  • 10. Takeda Pharmaceutical Company Limited
  • 11. Bayer AG
  • 12. Sigmapharm Laboratories, LLC
  • 13. Skyepharma Production SAS
  • 14. Pfizer Inc.
  • 15. Sumitomo Pharma Co., Ltd.
  • 16. Johnson & Johnson Services, Inc.
  • 17. NuCare Pharmaceuticals, Inc.
  • 18. Lunan Pharmaceutical Group
  • 19. B.M. Pharmaceuticals
  • 20. Merck & Co., Inc.
  • 21. Matinas Biopharma Holdings, Inc.
  • 22. Gilead Sciences, Inc.
  • 23. Sanofi S.A.
  • 24. Jolly Limited
  • 25. Abbott Laboratories
  • 26. GlaxoSmithKline PLC

LIST OF FIGURES

  • FIGURE 1. CRYPTOCOCCOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. CRYPTOCOCCOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CRYPTOCOCCOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CRYPTOCOCCOSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, 2023